Model-based comparisons of post-treatment free IgE and FEV1 between omalizumab asthma dosing tables in the United States and European Union.

Rui ZhuRik SchoemakerAurelie GautierXianbin TianCheryl HooiMing SimTheodore A OmachiAmita JoshiJin JinRyan Owen

Published in: British journal of clinical pharmacology (2024)

Despite the similar free IgE and FEV1 outcomes from simulations, this has not been clinically validated with respect to the registrational endpoint of reduction in annualized asthma exacerbations.

Keyphrases

chronic obstructive pulmonary disease
lung function
cystic fibrosis
allergic rhinitis
combination therapy